FindTrial
Sign In

gevokizumab

DRUG15 trials

Sponsors

XOMA (US) LLC, National Eye Institute (NEI), Institut de Recherches Internationales Servier, Novartis Pharmaceuticals, NSABP Foundation Inc

Conditions

Acne VulgarisAutoimmune Inner Ear DiseaseBehcet's Disease UveitisBehcet's UveitisChronic UveitisColon CancerColorectal CancerGastroesophageal Cancer

Phase 1

Gevokizumab for Active Scleritis
CompletedNCT01835132
National Eye Institute (NEI)Scleritis
Start: 2013-03-31End: 2016-02-29Updated: 2018-07-06
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
CompletedNCT03798626
Novartis PharmaceuticalsColorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
Start: 2019-05-22End: 2025-02-05Updated: 2026-04-01

Phase 2

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
CompletedNCT01498874
XOMA (US) LLCAcne Vulgaris
Start: 2011-12-31End: 2013-06-30Updated: 2014-03-04
Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand
CompletedNCT01683396
XOMA (US) LLCOsteoarthritis
Start: 2012-07-31End: 2014-02-28Updated: 2014-03-04
Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum
CompletedNCT01882504
XOMA (US) LLCPyoderma Gangrenosum
Start: 2013-05-31End: 2015-10-31Updated: 2016-02-03
Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand
CompletedNCT01882491
XOMA (US) LLCOsteoarthritis
Start: 2013-05-31End: 2014-02-28Updated: 2014-03-04
The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease
CompletedNCT01950312
XOMA (US) LLCAutoimmune Inner Ear Disease
Start: 2013-08-31End: 2015-12-31Target: 10Updated: 2016-02-03
A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy
WithdrawnNCT05178576
NSABP Foundation IncColon Cancer
Start: 2022-06-24End: 2027-02-28Updated: 2022-11-04

Phase 3

Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)
TerminatedNCT01965145
Institut de Recherches Internationales ServierBehcet's Uveitis
Start: 2012-11-30End: 2015-09-30Updated: 2020-01-03
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
TerminatedNCT02258867
XOMA (US) LLCBehcet's Disease Uveitis
Start: 2014-11-30End: 2015-11-30Updated: 2015-12-29
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
TerminatedNCT02315417
XOMA (US) LLCPyoderma Gangrenosum
Start: 2014-11-30End: 2016-03-31Updated: 2016-04-27
A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
TerminatedNCT02318914
XOMA (US) LLCPyoderma Gangrenosum
Start: 2014-11-30End: 2016-02-29Updated: 2016-04-27
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
TerminatedNCT02326740
XOMA (US) LLCPyoderma Gangrenosum
Start: 2014-12-31End: 2016-03-31Updated: 2016-04-27
Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)
TerminatedNCT02375685
Institut de Recherches Internationales ServierChronic Uveitis
Start: 2014-08-31End: 2015-11-30Updated: 2020-01-03

Unknown Phase

Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand
CompletedNCT02293564
XOMA (US) LLCOsteoarthritis
Start: 2013-03-31Updated: 2015-02-19

Related Papers

Phase Ib study of gevokizumab (GEVO) in combination with standard-of-care (SoC) anticancer therapies in patients (pts) with metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer (mGEC), and metastatic renal cell cancer (mRCC).
Journal of Clinical Oncology2025-01-27